Twists and Turns in Protein Expression: In Early Drug Discovery it’s Often Unclear Which Recombinant Proteins Will Be Affected by Changing the Host Cell

Angelo DePalma, Ph.D.

In Early Drug Discovery it’s Often Unclear Which Recombinant Proteins Will Be Affected by Changing the Host Cell When drug developers use different cell lines for manufacturing and preclinical research, they risk generating inconsistent results, proteins with various structures and functions. Then, confounded by variability, drug developers may lavish attention on irrelevant candidates and overlook promising candidates. To avoid misleading themselves, drug developers must find ways to avoid or account for protein variants, which include post-translational modifications, particularly alternative glycosylations. Such variants occur all too frequently among different host cell lines, an extensive body of literature documents. Variability is most evident when comparisons are made between mammalian and nonmammalian cells, says James Brady, Ph.D., vice president of technical applications and customer support at MaxCyte. “But depending on the protein that is being produced, even different mammalian cell lines, such as HEK and CHO, will exhibit substantial differences in post-translational modifications.” Differences can lead to altered protein stability, activity, or in vivo half-life. It is often unclear during the early drug discovery process which recombinant proteins will be affected by changing the host cell. However, misleading early-stage data are associated with significant costs and extended timelines. It therefore makes sense to adopt a single host cell for all stages of the development pipeline. That is the rationale behind MaxCyte’s flow electroporation transfection platform.

Visit Page

Related Application Notes

Optimum Growth™ Protocol for Insect Cells

... Sf9 and Sf21 insect cells are cell lines commonly used for expression of recombinant proteins using baculovirus sys...

See Application Note

Simplified Sample Prep for Open Access SEC-HPLC Detection using the Thomson Filter Vials

Routine analysis of samples containing cell culture media and/or supernatant by HPLC can lead to performance issues and...

See Application Note

Comparison of the Rapid Clear® Cap 3000 (patented) vs GE Capsule Filters for clarifying monospecific IgG

Two methods to clarify 10L of post transfected IgG harvested from culture are compared. The culture was harvested on da...

See Application Note

Improved DNA Protocol for E.coli with Plasmid+® Media

Plasmid+® liquid media is an enriched media specifically designed for plasmid DNA production. Plasmid+® supports much h...

See Application Note

Title

Twists and Turns in Protein Expression: In Early Drug Discovery it’s Often Unclear Which Recombinant Proteins Will Be Affected by Changing the Host Cell

Description

In Early Drug Discovery it’s Often Unclear Which Recombinant Proteins Will Be Affected by Changing the Host Cell When drug developers use different cell lines for manufacturing and preclinical research, they risk generating inconsistent results, proteins with various structures and functions. Then, confounded by variability, drug developers may la...

Visit Page

Product Used

Optimum Growth™ 125mL Flask

PTFE 0.2µm Vent Cap for Increased Aeration | Sterile

pn#931110

Related Products

© 2021 Thomson |
Solutions At Work™

LinkedIn